

GILEAD SCIENCES INC  
Form 8-K  
May 11, 2004

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):**

**May 11, 2004**

**GILEAD SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

(State or other jurisdiction of  
incorporation or organization)

**0-19731**

(Commission File Number)

**94-3047598**

(I.R.S. Employer  
Identification No.)

**333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA**

(Address of principal executive offices)

**94404**

(Zip Code)

**(650) 574-3000**

(Registrant's telephone number, including area code)



**ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.**

On May 3, 2004, Gilead Sciences, Inc., a Delaware corporation, issued a press release announcing that it has implemented a stock trading program in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. A copy of the press release is filed as Exhibit 99.1 to this report. Paul Berg, PhD, a member of Gilead's Board of Directors, has established a stock trading plan in accordance with Gilead's stock trading program under Rule 10b5-1. Other participating Gilead executives and Board members may establish pre-arranged stock trading plans to buy or sell pre-determined amounts of Gilead stock over time under Gilead's 10b5-1 stock trading program.

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits

Exhibit Number	Description
99.1	Press Release, issued by Gilead Sciences, Inc. on May 3, 2004

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	<b>GILEAD SCIENCES, INC.</b>	
	(registrant)	
	/s/ John F. Milligan	
	John F. Milligan	
	Executive Vice President and	
	Chief Financial Officer	
Date:	May 11, 2004	

Exhibit Index

Exhibit Number	Description
99.1	Press Release, issued by Gilead Sciences, Inc. on May 3, 2004